相关实验视频

Updated: May 5, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

作为代谢功能障碍相关脂肪肝疾病 (MAFLD) 的潜在目标的KRT23:来自生物信息学分析,人类基因多态化和动物实验的证据

Yangmin Hao^1,2, Tao Zhang³, Shaliyan Tuerxunmaimaiti^1,2

¹State Key Laboratory of Pathogenesis, Prevention, and Treatment of High Incidence Diseases in Central Asia, Urumqi, Xinjiang, People's Republic of China.

International journal of general medicine

|June 9, 2025

概括

在KRT23的遗传变异与代谢功能障碍相关的脂肪肝疾病 (MAFLD) 有关. 特定的KRT23基因多态性影响MAFLD风险,而KRT23的高表达与该疾病相关,表明KRT23是潜在的治疗标.

科学领域:

遗传学是一个遗传学.
肝病学肝病学是一种肝病学.
代谢疾病代谢疾病

背景情况:

与代谢功能障碍相关的脂肪肝疾病 (MAFLD) 很普遍,遗传因素也起着作用.
氨酸23 (KRT23),一种参与新陈代谢调节的肝蛋白,在MAFLD遗传学中没有得到充分研究.

研究的目的:

在新疆人口中调查KRT23基因多态,KRT23表达和MAFLD之间的关联.
探索KRT23作为MAFLD的潜在遗传标记物和治疗点.

主要方法:

在1,795名MAFLD患者和对照中分析KRT23多态 (rs72826004,rs2269859).
使用分子生物学技术 (ELISA,西部斑块,qRT‒PCR,IHC) 在人类血清/肝脏组织和小鼠MAFLD模型中评估KRT23表达.
对MAFLD相关基因的生物信息查和丰富分析.

主要成果:

rs72826004 TT基因型与MAFLD风险增加有关 (OR:2.156),而rs2269859 TT基因型显示有保护作用 (OR:0.306).
与对照人群相比,MAFLD患者在血清和肝脏组织中表现出明显更高的KRT23蛋白和mRNA水平.
在饮食诱导和遗传性MAFLD小鼠模型中证实了KRT23表达的升高.

结论:

KRT23基因多态性与MAFLD发生有关,特定的基因型作为风险或保护因素.
增加KRT23表达 (蛋白质和mRNA) 与MAFLD有关.
KRT23代表了管理MAFLD的潜在治疗目标.

关键词:

在 KRT2323 里面.马夫尔德 (MAFLD) 是一个名为马夫尔德的生物信息学是一种生物信息学.临床数据和动物实验.基因多形态的多态化质素 23 23 质素 23 与代谢功能障碍相关的脂肪肝疾病.

更多相关视频

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment

Published on: June 2, 2023

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...